Loading...
Market
How many patients will receive CASGEVY™ treatment in England by end of 2024?
2
Resolution / Starting Odds
Less than 100 • 25%
100 to 500 • 25%
500 to 1000 • 25%
More than 1000 • 25%
NHS official reports and statistics
Story
CASGEVY™ CRISPR-Based Therapy for Beta Thalassemia Approved in England
Aug 7, 2024, 11:25 PM
Patients in England suffering from a rare blood disorder known as transfusion-dependent beta thalassemia will soon have access to the world's first CRISPR-based medicine, CASGEVY™. This development follows a reimbursement agreement reached between Vertex Pharmaceuticals and U.K. officials. The National Health Service (NHS) will begin rolling out the gene therapy, which is a collaboration between Vertex Pharmaceuticals and CRISPR Therapeutics, marking a significant advancement in the treatment of this condition.
View original story
Similar markets
Less than 10,000 • 25%
10,000 to 20,000 • 25%
20,000 to 30,000 • 25%
More than 30,000 • 25%
Less than 100,000 • 25%
100,000 to 150,000 • 25%
150,001 to 220,000 • 25%
More than 220,000 • 25%
Less than 100 • 25%
100 - 500 • 25%
500 - 1000 • 25%
More than 1000 • 25%
Less than 1,000 • 25%
1,000 to 5,000 • 25%
5,000 to 10,000 • 25%
More than 10,000 • 25%
Less than 100 • 33%
100 to 500 • 34%
More than 500 • 33%
Less than 100 patients • 25%
100 to 500 patients • 25%
501 to 1000 patients • 25%
More than 1000 patients • 25%
Less than 500 • 25%
500 to 1000 • 25%
1001 to 2000 • 25%
More than 2000 • 25%
Less than 100 • 25%
100 - 500 • 25%
500 - 1000 • 25%
More than 1000 • 25%
Less than 50 hospitals • 25%
50 to 100 hospitals • 25%
101 to 200 hospitals • 25%
More than 200 hospitals • 25%
Yes • 50%
No • 50%
Less than 50,000 • 25%
50,000 to 75,000 • 25%
75,000 to 100,000 • 25%
More than 100,000 • 25%
Less than 200 • 25%
200 to 400 • 25%
400 to 600 • 25%
More than 600 • 25%